Boston Scientific has announced results of clinical trials of its platinum-chromium stent systems.

The studies show improvements in the ION Platinum Chromium (PtCr) Paclitaxel-Eluting Stent System (TAXUS Element), compared to the currently available TAXUS Liberte Paclitaxel-Eluting Stent System.

Results were presented at the American College of Cardiology Annual Scientific Sessions by Dean Kereiakes, medical director at the Christ Hospital Heart and Vascular Center and the Lindner Research Center in Cincinnati.

The ION Stent demonstrated "significantly" lower rates of major adverse cardiac events, target lesion failure and myocardial infarction, despite the ION and TAXUS Liberte Stents employing the same drug and polymer, said Dr Kereiakes.

"This study demonstrates that alloy composition, stent design and strut thickness may influence angiographic and clinical outcomes following drug-eluting stent deployment," he added.

Hank Kucheman, executive vice-president and group president for cardiology, rhythm and vascular for Boston Scientific, said the results reveal the clinical benefits of the PtCr Stent Series, which have already been seen in Europe.

The ION Stent System features an innovative PtCr alloy and new stent design, which the company says offers "greater strength, enhanced deliverability and exceptional visibility".

It expects to launch the ION Stent System in the US by mid-2011.

Source:



Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data (03/04/11) 

© Adfero Ltd